Patient case (clinical description): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient's own account: I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Clinical trial: Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19

Eligibility criteria:
Inclusion Criteria:

          -  Population over 18 years of age up to 70, sample size 30.

          -  Subjects with mild to moderate* symptoms of respiratory illness caused by 2019
             coronavirus infection as defined below: Mild disease (uncomplicated):

          -  Diagnosed with COVID-19 by a standardized RT-PCR assay and Mild symptoms, such as
             fever, runny nose, mild cough, sore throat, malaise, headache, muscle pain, or
             discomfort, but no shortness of breath and No signs of more serious lower airway
             disease.

          -  RR <20, HR <90, oxygen saturation (pulse oximetry)> 93% in ambient air.

             *Moderate illness:

          -  Diagnosed with COVID-19 by a standardized RT-PCR assay and

          -  In addition to the above symptoms, more significant lower respiratory symptoms,
             including difficulty breathing (at rest or with exertion) or

          -  Signs of moderate pneumonia, including RR ≥ 20 but <30, HR ≥ 90 but less than 125,
             oxygen saturation (pulse oximetry)> 93% in ambient air, and

          -  If available, X-ray or computed tomography-based lung infiltrates <50% present 3.
             12-lead ECG at rest clinically normal at the screening visit or, if abnormal, not
             considered clinically significant by the lead investigator.

             4. The subject (or legally authorized representative) provides her informed written
             consent before starting any study procedure.

             5. Understand and agree to comply with planned study procedures. 6. Women of
             childbearing potential must agree to use at least one medically accepted method of
             contraception (eg, barrier contraceptives [condom or diaphragm with a spermicidal
             gel], hormonal contraceptives [implants, injectables, combined oral contraceptives,
             transdermal patches or rings) ] or intrauterine devices) for the duration of the
             study.

        Exclusion Criteria:

          -  None
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 70 Years

Eligibility (NLI label): Contradiction